GW26-e0266 Safety and effectiveness of Tadalafil on PAH from a post-marketing surveillance (Investigation on all patients in Japan, interim data)
Abstract
To present the interim analysis of long-term safety and effectiveness profiles of tadalafil (Adcirca) in daily clinical practice from ongoing All-patient Investigation in patients with pulmonary arterial hypertension (PAH).
818 case report forms from patients receiving tadalafil were collected from
Read the paper
Related studies
- Protective effects of tadalafil and N-acetyl cysteine therapy on cisplatin-induced testicular toxicity
- Understanding and treating ejaculatory dysfunction in men with diabetes mellitus
- An Eco-Friendly Solid-State Electrode Modified With ZnO Nanoparticles Decorated With MWCNT as an Electrochemical Sensor for the Determination of Avanafil in Pure Form, Dosage Form and Human Plasma
- The Use of Generative AI for Scientific Literature Searches for Systematic Reviews: ChatGPT and Microsoft Bing AI Performance Evaluation
- Combinations of Freeze-Dried Amorphous Vardenafil Hydrochloride with Saccharides as a Way to Enhance Dissolution Rate and Permeability
- Return to Sport, Reinjury Rate, and Tissue Changes after Muscle Strain Injury: A Narrative Review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.